Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME

https://doi.org/10.20996/1819-6446-2014-10-1-37-42

Full Text:

Abstract

Aim. To assess the role of the activation of matrix metalloproteinase-1 zymogen (ProMMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the development of left ventricular (LV) hypertrophy in patients with arterial hypertension (HT) and metabolic syndrome (MS) with varying degree of obesity.

Material and methods. 108 patients with HT and MS divided into 3 groups according to body mass index, and 28 healthy women were studied. Intracardiac blood flow and ProMMP-1 and TIMP-1 levels were assessed.

Results. Disbalance in the ProMMP-1 and TIMP-1 systems  is associated with the severity of left ventricular remodeling and grade of obesity. The changes in LV structure and geometry and activation ProMMP-1 with a deficit of TIMP-1 were most significant in patients with HT and grade 3 obesity (respectively 7.7±0.61 and 183.6±17.2 ng/ml in grade 3 obesity vs 3.5±0.3 and 291.7±22.4 ng/ml in grade 1 obesity; p<0.05). Associations between hemodynamic parameters and levels of ProMMP-1 [withLVmass index (LVMI): r=0.47; p<0.05] and TIMP-1 (with LVMI: r=-0.39;  p<0.05) were determined.

Conclusion. Changes in the ProMMP-1 and TIMP-1 system in women with HT and MS are associated with the severity ofLVhypertrophy.

About the Authors

A. N. Zakirova
Bashkir State Medical University, Ufa
Russian Federation


E. Z. Fatkullina
Bashkir State Medical University, Ufa
Russian Federation


N. E. Zakirova
Bashkir State Medical University, Ufa
Russian Federation


References

1. Oganov RG, Shalnova SA, Deev AD. Hypertension, mortality from cardiovascular diseases and contribute to the life expectancy of the population. Prevention and Health Promotion 2001; (3): 3-7. Russian (Оганов Р.Г., Шальнова С.А., Деев А.Д. Артериальная гипертония, смертность от сердечнососудистых заболеваний и вклад в продолжительность жизни населения. Профилактика Заболеваний и Укрепление Здоровья 2001; (3): 3-7).

2. Glaser MG, Astashkin EI. Obesity and hypertension. Problems of Women's Health 2008; 3 (4): 23-33. Russian (Глезер М.Г., Асташкин Е.И. Ожирение и артериальная гипертония. Проблемы Женского Здоровья 2008; 3(4): 23-33).

3. Conradi AO, Zhukova AV, Vinnick TA, Shlyakhto EV. Structure-function parameters infarction in hypertensive patients depending on body weight, obesity and type status of carbohydrate metabolism. Arterial Hypertension 2002; 8 (1): 7-12. Russian (Конради А.О., Жукова А.В., Винник Т.А., Шляхто Е.В. Стуктурно-функциональные параметры миокарда у больных гипертонической болезнью в зависимости от массы тела, типа ожирения и состояния углеводного обмена. Артериальная Гипертензия 2002; 8(1): 7-12).

4. Chazova IE, Michka VB, Sharipova GH. Features of cardiac damage in the metabolic syndrome in patients with arterial hypertension. Cardiovascular Therapy and Prevention 2008; 7 (8): 20-6. Russian (Чазова И.Е., Мычка В.Б., Шарипова Г.Х. Особенности поражения сердца при метаболическом синдроме у больных артериальной гипертензией. Кардиоваскулярная Терапия и Профилактика 2008; 7 (8): 20-6).

5. Simone de G., Palmieri V., Bella J.N. Association of left ventricular hypertrophy with metabolic risk factors: the Hyper GEN study. J Hypertens 2002; 20: 323-331.

6. Kapelko VI. Myocardial remodeling: the role of matrix metalloproteinases. Cardiology 2001; (6): 49-55. Russian (Капелько В.И., Ремоделирование миокарда: роль матриксных металлопротеиназ. Кардиология 2001; (6): 49-55).

7. Hezheva FM, Mazur NA. Serum markers of fibrosis in patients with arterial hypertension. Cardiology 2006 (3) 46: 64-7. Russian (Хежева Ф.М., Мазур Н.А. Сывороточные маркеры фиброза у больных артериальной гипертонией. Кардиология 2006; (3); 46: 64-7).

8. Turna AA, Toguzov RT. Matrix metalloproteinases and cardiovascular disease. Arterial Hypertension 2009; 15 (5): 533-8. Russian (Турна А.А., Тогузов Р.Т. Матриксные металлопротеиназы и сердечно-сосудистые заболевания. Артериальная Гипертензия 2009; 15 (5): 533-8).

9. Li J, Schwimmbeck R.L, Tshope C. et. al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiolovasc Res 2002; 56 (2): 235-47.

10. Hoerstra R., Eskens F.A.L.M., Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. The Oncologist 2001; 6 (5): 415-27.

11. Lindsay M.M., Maxwell P., Dunn F.G. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136-41.

12. Pecherin TB, Gruzdeva OV, Kashtalap VV, Barbarash OL. The role of matrix metalloproteinases in the assessment of prognosis in patients with myocardial infarction with ST segment elevation during the hospital stay. Cardiology 2013; 6 (53): 18-24. Russian (Печерина Т.Б., Груздева О.В., Кашталап В.В., Барбараш О.Л. Роль матриксных металлопротеиназ в оценке прогноза у больных инфарктом миокарда с подъемом сегмента ST в период пребывания в стационаре. Кардиология 2013; 6 (53): 18-24).

13. Flamant M., Placier S., Dubroca С. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007; 50: 212-8.

14. Mukherjeс R., Brinsa T.A., Dowdy K.B. et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003; 107 (4): 618-25.

15. Kovalev ON, White NV. Modern aspects of the pathogenesis of hypertension. International Journal of Medicine 2005; (4): 10-3. Russian (Ковалева О.Н., Белая Н.В. Современные аспекты патогенеза артериальной гипертензии. Международный Медицинский Журнал 2005; (4): 10-3).

16. Vizir VA, Voloshin IN. The relationship of plasma markers of degradation of extracellular matrix with end-organ damage in hypertension. Ukrainian Journal of Cardiology 2011; (5): 45-50. Ukrainian (Визир В.А., Волошина И.Н. Взаимосвязь плазменных маркеров деградации экстрацеллюлярного матрикса с поражением органов-мишеней при гипертонической болезни. Украинский Кардиологический Журнал 2011; (5): 45-50).

17. Ibrahim MM. The role of transforming growth factor β1 and matrix metalloproteinases in the development of left ventricular hypertrophy in hypertension. Ukrainian Journal of Cardiology 2009; (1): 108-9. Ukrainian (Ибрагим М.М. Роль трансформирующего фактора роста β1 и матриксных металлопротеиназ в развитии гипертрофии левого желудочка при артериальной гипертензии. Украинский Кардиологический Журнал 2009; (1): 108-9).

18. Zakirova AN, Fatkullina EZ, Zakirova NE. Markers of myocardial fibrosis and left ventricular remodeling in women with hypertension and metabolic syndrome. Problems of Women's Health 2013; 4 (8): 43-8. Russian (Закирова А.Н., Фаткуллина Е.З., Закирова Н.Э. Маркеры фиброза миокарда и ремоделирование левого желудочка у женщин с артериальной гипертонией и метаболическим синдромом. Проблемы Женского Здоровья 2013; 4(8): 43-8).

19. National guidelines for diagnosis and treatment of metabolic syndrome. Cardiovascular Therapy and Prevention 2007; 6 (6) suppl 2: 1-20. Russian (Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваскулярная Терапия и Профилактика 2007;6 (6) Приложение 2: 1-20).

20. Bornstein P., Sage E.N. Matricellular proteins: extracellular modulators of аll function. Curr Opin Cel Biol 2002; 14(5): 608-16.

21. Saffurian S., Colleier I.E., Marmer B.L. et al. Interstitial collagenase is a Brownian ratchet drive by proteolysis of collagen. Science 2004; 306 (5693): 108-11.

22. Kopitsa NP, Belaya NI, Titarenko NV. Methods of diagnosis of myocardial fibrosis in hypertensive patients. Arterial Hypertension 2008; 2 (2): 39-42. Russian (Копица Н.П., Белая Н.И, Титаренко Н.В. Методы диагностики миокардиального фиброза у больных артериальной гипертонией. Артериальная Гипертензия 2008; 2(2): 39-42.

23. Diez J., Panizo A., Gil M.J. et al. Serun markers of collagen type 1 metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996; 93 (5): 1026-1032.

24. Appel G.B. Angiotensin 11 receptor antagonist: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis 2004; 2: 105-115.

25. Mesut Demir, Esmeray Acarturs, Tamep Inal. Procollagen type 1 carboxy-terminale peptide shows ventricular hypertrophy and diastolic dysfunction in hypertensive patients. Cardiovasc Pathology 2007; 16(2): 69-74.

26. Tayebjee M.H., Nadar S., Blann A.D. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypert 2004; 17: 764-9.


For citation:


Zakirova A.N., Fatkullina E.Z., Zakirova N.E. THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME. Rational Pharmacotherapy in Cardiology. 2014;10(1):37-42. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-1-37-42

Views: 396


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)